Overexpression of COX-2 but not indoleamine 2,3-dioxygenase-1 enhances the immunosuppressive ability of human umbilical cord-derived mesenchymal stem cells

Li,Dong; Han,Yan; Zhuang,Yong; Fu,Jinqiu; Liu,Huan; Shi,Qing; Ju,Xiuli

doi:10.3892/ijmm.2015.2137

Overexpression of COX-2 but not indoleamine 2,3-dioxygenase-1 enhances the immunosuppressive ability of human umbilical cord-derived mesenchymal stem cells

Authors:
- Dong Li
- Yan Han
- Yong Zhuang
- Jinqiu Fu
- Huan Liu
- Qing Shi
- Xiuli Ju
View Affiliations

Affiliations: Cryomedicine Laboratory, Qilu Hospital, Shandong University, Ji'nan, Shandong 250012, P.R. China
Published online on: March 13, 2015 https://doi.org/10.3892/ijmm.2015.2137
Pages: 1309-1316

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Owing to their immunosuppressive properties mesenchymal stem cells (MSCs) are widely applicable in the treatment of autoimmune disease. The aim of this study was to investigate whether the indoleamine 2,3-dioxygenase-1 (IDO-1) and cyclooxygenase-2 (COX-2) genes enhanced the immunosuppressive functional ability of MSCs following stable transfection. To strengthen the immunomodulatory ability of MSCs, IDO-1 and COX-2 were overexpressed in umbilical cord progenitor cell-derived MSCs using recombinant plasmids and electroporation. RT-qPCR analysis and western blotting confirmed the expression of IDO-1 and COX-2 in transfected MSCs. Further functional assays in co-culture experiments, including lymphocyte proliferation and cytotoxicity assays showed that COX-2‑transfected MSCs possessed more potent immunomodulatory cells than the untreated MSCs, or MSCs transfected with IDO-1. Additionally, synthesis of interferon-γ and tumor necrosis factor-α (TNF-α) was significantly inhibited in lymphocytes co-cultured with COX-2‑transfected MSCs, which was consistent with changes in immune-related genes in MSCs. An enhanced expression of IDO-1, COX-2, heme-oxygenase-1, inducible nitric-oxide synthase, TNF-α-stimulated gene/protein-6, transforming growth factor-β (TGF-β), human leukocyte antigen molecule 5 (HLA-G5) and interleukin-10 (IL-10) was identified following COX-2 transfection. We showed that the overexpression of COX-2 enhanced the immunosuppressive function of MSCs. COX-2‑modified MSCs more potently inhibited the activation and proliferation of peripheral blood mononuclear cells.

View Figures

View References

1	Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI and Martin KR: Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci. 51:2051–2059. 2010. View Article : Google Scholar :
2	Matsushita K, Morello F, Wu Y, et al: Mesenchymal stem cells differentiate into renin-producing juxtaglomerular (JG)-like cells under the control of liver X receptor-alpha. J Biol Chem. 285:11974–11982. 2010. View Article : Google Scholar : PubMed/NCBI
3	Williams AR and Hare JM: Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 109:923–940. 2011. View Article : Google Scholar : PubMed/NCBI
4	Musumeci G, Lo Furno D, Loreto C, et al: Mesenchymal stem cells from adipose tissue which have been differentiated into chondrocytes in three-dimensional culture express lubricin. Exp Biol Med (Maywood). 236:1333–1341. 2011. View Article : Google Scholar
5	Jurewicz M, Yang S, Augello A, et al: Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes. 59:3139–3147. 2010. View Article : Google Scholar : PubMed/NCBI
6	Curley GF, Hayes M, Ansari B, et al: Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax. 67:496–501. 2012. View Article : Google Scholar
7	Li J, Li D, Liu X, Tang S and Wei F: Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm (Lond). 9:332012. View Article : Google Scholar
8	Hu KX, Sun QY, Guo M and Ai HS: The radiation protection and therapy effects of mesenchymal stem cells in mice with acute radiation injury. Br J Radiol. 83:52–58. 2010. View Article : Google Scholar : PubMed/NCBI
9	Zoja C, Garcia PB, Rota C, et al: Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. Am J Physiol Renal Physiol. 303:F1370–F1381. 2012. View Article : Google Scholar : PubMed/NCBI
10	Nauta AJ and Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood. 110:3499–3506. 2007. View Article : Google Scholar : PubMed/NCBI
11	Aggarwal S and Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105:1815–1822. 2005. View Article : Google Scholar
12	Atoui R, Shum-Tim D and Chiu RC: Myocardial regenerative therapy: immunologic basis for the potential ‘universal donor cells’. Ann Thorac Surg. 86:327–334. 2008. View Article : Google Scholar : PubMed/NCBI
13	Rice CM, Kemp K, Wilkins A and Scolding NJ: Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet. 382:1204–1213. 2013. View Article : Google Scholar : PubMed/NCBI
14	Kim N, Im KI, Lim JY, et al: Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol. 92:1295–1308. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ning H, Yang F, Jiang M, et al: The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 22:593–599. 2008. View Article : Google Scholar : PubMed/NCBI
16	Ball LM, Bernardo ME, Roelofs H, et al: Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 110:2764–2767. 2007. View Article : Google Scholar : PubMed/NCBI
17	Lazarus HM, Koc ON, Devine SM, et al: Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 11:389–398. 2005. View Article : Google Scholar : PubMed/NCBI
18	Koç ON, Gerson SL, Cooper BW, et al: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol. 18:307–316. 2000.PubMed/NCBI
19	Le Blanc K, Samuelsson H, Gustafsson B, et al: Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 21:1733–1738. 2007. View Article : Google Scholar : PubMed/NCBI
20	Ji JF, He BP, Dheen ST and Tay SS: Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells. 22:415–427. 2004. View Article : Google Scholar : PubMed/NCBI
21	Devine SM, Cobbs C, Jennings M, Bartholomew A and Hoffman R: Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 101:2999–3001. 2003. View Article : Google Scholar
22	Jung JW, Kwon M, Choi JC, et al: Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J. 54:1293–1296. 2013. View Article : Google Scholar : PubMed/NCBI
23	Spaggiari GM, Abdelrazik H, Becchetti F and Moretta L: MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 113:6576–6583. 2009. View Article : Google Scholar : PubMed/NCBI
24	Opitz CA, Litzenburger UM, Lutz C, et al: Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells. 27:909–919. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sato K, Ozaki K, Oh I, et al: Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 109:228–234. 2007. View Article : Google Scholar
26	Yoo SW, Chang DY, Lee HS, et al: Immune following suppression mesenchymal stem cell transplantation in the ischemic brain is mediated by TGF-β. Neurobiol Dis. 58:249–257. 2013. View Article : Google Scholar : PubMed/NCBI
27	Djouad F, Charbonnier LM, Bouffi C, et al: Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 25:2025–2032. 2007. View Article : Google Scholar : PubMed/NCBI
28	Németh K, Leelahavanichkul A, Yuen PS, et al: Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 15:42–49. 2009. View Article : Google Scholar
29	Sui W, Hou X, Che W, et al: Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clin Immunol. 148:186–197. 2013. View Article : Google Scholar : PubMed/NCBI
30	Luz-Crawford P, Kurte M, Bravo-Alegria J, et al: Mesenchymal stem cells generate a CD4⁺CD25⁺Foxp3⁺ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 4:652013. View Article : Google Scholar
31	Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC and Moretta L: Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 111:1327–1333. 2008. View Article : Google Scholar
32	English K, Ryan JM, Tobin L, Murphy MJ, Barry FP and Mahon BP: Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4⁺CD25(High) forkhead box P3⁺ regulatory T cells. Clin Exp Immunol. 156:149–160. 2009. View Article : Google Scholar : PubMed/NCBI
33	Duffy MM, Pindjakova J, Hanley SA, et al: Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol. 41:2840–2851. 2011. View Article : Google Scholar : PubMed/NCBI
34	Yañez R, Oviedo A, Aldea M, Bueren JA and Lamana ML: Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res. 316:3109–3123. 2010. View Article : Google Scholar : PubMed/NCBI
35	Pittenger MF and Martin BJ: Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 95:9–20. 2004. View Article : Google Scholar : PubMed/NCBI
36	Tamama K, Kawasaki H and Wells A: Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol. 2010:7953852010. View Article : Google Scholar : PubMed/NCBI
37	Freyman T, Polin G, Osman H, et al: A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J. 27:1114–1122. 2006. View Article : Google Scholar : PubMed/NCBI
38	Schroder K, Hertzog PJ, Ravasi T and Hume DA: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 75:163–189. 2004. View Article : Google Scholar
39	Pfeffer K: Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 14:185–191. 2003. View Article : Google Scholar : PubMed/NCBI
40	Liu H, Lu K, MacAry PA, et al: Soluble molecules are key in maintaining the immunomodulatory activity of murine mesenchymal stromal cells. J Cell Sci. 125:200–208. 2012. View Article : Google Scholar : PubMed/NCBI
41	Qi Y, Jiang D, Sindrilaru A, et al: TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol. 134:526–537. 2014. View Article : Google Scholar
42	Prockop DJ: Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells. 31:2042–2046. 2013. View Article : Google Scholar : PubMed/NCBI
43	Selmani Z, Naji A, Zidi I, et al: Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4⁺CD25^highFOXP3⁺ regulatory T cells. Stem Cells. 26:212–222. 2008. View Article : Google Scholar
44	Ren G, Zhang L, Zhao X, et al: Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2:141–150. 2008. View Article : Google Scholar : PubMed/NCBI
45	Chabannes D, Hill M, Merieau E, et al: A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood. 110:3691–3694. 2007. View Article : Google Scholar : PubMed/NCBI
46	Brusko TM, Wasserfall CH, Agarwal A, Kapturczak MH and Atkinson MA: An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4⁺CD25⁺ regulatory T cells. J Immunol. 174:5181–5186. 2005. View Article : Google Scholar : PubMed/NCBI